Oncodesign Precision Medicine
Oncodesign Precision Medicine Société anonyme, a biopharmaceutical company, engages in the precision medicine business. The company's product pipeline consist of OPM-101, a RIPK2 inhibitor for the treatment of inflammatory bowel disease and immuno-oncology; OPM-102 to treat cancer; and OPM-201, a LRRK2 inhibitor for the treatment of Parkinson's disease. It also focuses on the development of a rad… Read more
Oncodesign Precision Medicine - Asset Resilience Ratio
Oncodesign Precision Medicine (ALOPM) has an Asset Resilience Ratio of 60.21% as of December 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2022–2024)
This chart shows how Oncodesign Precision Medicine's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Oncodesign Precision Medicine's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €10.01 Million | 60.21% |
| Total Liquid Assets | €10.01 Million | 60.21% |
Asset Resilience Insights
- Very High Liquidity: Oncodesign Precision Medicine maintains exceptional liquid asset reserves at 60.21% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Oncodesign Precision Medicine Industry Peers by Asset Resilience Ratio
Compare Oncodesign Precision Medicine's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
ESSA Pharma Inc
NASDAQ:EPIX |
Biotechnology | 21.42% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Oncodesign Precision Medicine (2022–2024)
The table below shows the annual Asset Resilience Ratio data for Oncodesign Precision Medicine.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 45.19% | €4.84 Million | €10.71 Million | -15.02pp |
| 2023-12-31 | 60.21% | €10.01 Million | €16.63 Million | +59.53pp |
| 2022-12-31 | 0.68% | €125.00K | €18.37 Million | -- |